Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome

Font, Patricia; Subirá, Dolores; Mtnez-Chamorro, C.; Castañón, Susana; Arranz, Eva; Ramiro, Soraya; Gil-Fernández, J J; López-Pascual, J.; Alonso, Arancha; Perez-Saenz, Maria Angeles; Aláez, Concepción; Renedo, Mónica; Blas, Carlos; Escudero, Antonio; Fdez-Rañada, J.M.

doi:10.1016/j.leukres.2005.11.026

Cited by 24 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lineage marker expression on myeloid progenitors in this particular MDS subgroup is in line with a study by Font et al, who reported CD7 expression in 18 of 29 patients with RA with or without RS. 20 These observations underscore the concept that MDS is a stem-cell disease. 1,2 In addition to aberrancies on myeloid blasts, numerical changes in precursor B cells may also be indicative for MDS.…”

Section: Discussionmentioning

confidence: 83%

“…7 Several reports indicate that characterization of dysplastic cells by flow cytometry in patients with MDS is feasible, and this approach enables the identification of specific aberrancies on both the immature and mature myelomonocytic cells. [8][9][10][11][12][13][14][15][16][17][18][19][20] However, extensive correlations with clinical parameters are lacking. The current study aimed to investigate aberrancies on progenitor and maturing cells of the myelomonocytic lineage in low-and intermediate-1 (int-1)-risk MDS by 4-color flow cytometry.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of distinct prognostic subgroups in low- and intermediate-1–risk myelodysplastic syndromes by flow cytometry

Loosdrecht

Westers

Westra

et al. 2008

Blood

209

248

View full text Add to dashboard Cite

The World Health Organization (WHO) classification contributes to refined classification and prognostication of myelodysplastic syndromes (MDSs). Flow cytometry might add significantly to diagnostic and prognostic criteria. Our analysis of bone marrow samples from 50 patients with MDS showed aberrant expression of differentiation antigens in the myelomonocytic lineage. This also accounted for refractory anemia (RA) with or without ringed sideroblasts (RS), indicating multilineage dysplasia. In 38% of patients, CD34 ؉ myeloid blasts expressed CD5, CD7, or CD56. Flow cytometry data were translated into a numerical MDS flow-score. Flow-scores increased significantly from RA with or without RS, refractory cytopenia with multilineage dysplasia (RCMD) with or without RS up to refractory anemia with excess of blasts-1 (RAEB-1) and RAEB-2. No significant differences were observed between WHO cytogenetic subgroups. Flow-scores were highly heterogeneous within International Prognostic Scoring System (IPSS) subgroups. Patients in progression to advanced MDS or acute myeloid leukemia had a significantly higher flow-score compared with non-transfusion-dependent patients. In 60% of patients with transfusion dependency or progressive disease, myeloid blasts expressed CD7 or CD56, in contrast to only 9% of non-transfusiondependent patients. Moreover, all patients with pure RA with or without RS with aberrant myeloid blasts showed an adverse clinical course. In conclusion, flow cytometry in MDS identified aberrancies in the myelomonocytic lineage not otherwise determined by cytomorphology. In addition, flow cytometry identified patients at risk for transfusion dependency and/or progressive disease independent of known risk groups, which might have impact on treatment decisions and the prognostic scoring system in the near future.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Identification of distinct prognostic subgroups in low- and intermediate-1–risk myelodysplastic syndromes by flow cytometry

Loosdrecht

Westers

Westra

et al. 2008

Blood

209

248

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7] Aberrant expression of certain antigens (CD7 and/or TdT) on myeloblast cells has been shown to correlate with poor clinical outcome. 6,8,9 These studies indicate that FCM shows promise in contributing significantly to the diagnosis and prognosis of MDS.…”

Section: Flow Cytometry In Myelodysplastic Syndromes In Relation To Mmentioning

confidence: 90%

“…4 For instance, expression of CD7 on myeloblasts was shown to correlate with poor clinical outcome, and CD15 expression on myeloblasts was associated with good prognosis. 6,8,9 Another issue related to interpretation of data regards the minimal number of abnormalities by FCM necessary to diagnose a patient as having MDS. The presence of multiple aberrancies has a higher predictive value for MDS than single aberrancies.…”

Section: Future Directions For Flow Cytometry In Myelodysplastic Syndmentioning

confidence: 99%

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

et al. 2009

Self Cite

View full text Add to dashboard Cite

The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more cell lineages and increased risk of evolution to acute myeloid leukemia (AML). Recent advances in immunophenotyping of hematopoietic progenitor and maturing cells in dysplastic bone marrow point to a useful role for multiparameter flow cytometry (FCM) in the diagnosis and prognostication of myelodysplastic syndromes. In March 2008, representatives from 18 European institutes participated in a European LeukemiaNet (ELN) workshop held in Amsterdam as a first step towards standardization of FCM in myelodysplastic syndromes. Consensus was reached regarding standard methods for cell sampling, handling and processing. The group also defined minimal combinations of antibodies to analyze aberrant immunophenotypes and thus dysplasia. Examples are altered numbers of CD34 + precursors, aberrant expression of markers on myeloblasts, maturing myeloid cells, monocytes or erythroid precursors and the expression of lineage infidelity markers. When applied in practice, aberrant FCM patterns correlate well with morphology, the subclassification of myelodysplastic syndromes, and prognostic scoring systems. However, the group also concluded that despite strong evidence for an impact of FCM in myelodysplastic syndromes, further (prospective) validation of markers and immunophenotypic patterns are required against control patient groups as well as further standardization in multi-center studies. Standardization of FCM in myelodysplastic syndromes may thus contribute to improved diagnosis and prognostication of myelodysplastic syndromes in the future. Cancer and Immunology, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. E-mail: a.vandeloosdrecht@vumc.nl © F e r r a t a S t o r t i F o u n d a t i o n

show abstract

“…27,28 A decrease in CD38 expression on CD34 þ myeloid progenitor cells has also been reported as a rather typical aberrancy in MDS. 29,30 Analysis of the maturing myeloid and monocytic compartment Definition of neutrophils.…”

Section: Implementation Of Multiparameter Fc Analysis In Mdsmentioning

confidence: 95%

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

et al. 2012

View full text Add to dashboard Cite

Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome

Cited by 24 publications

References 25 publications

Identification of distinct prognostic subgroups in low- and intermediate-1–risk myelodysplastic syndromes by flow cytometry

Identification of distinct prognostic subgroups in low- and intermediate-1–risk myelodysplastic syndromes by flow cytometry

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

Contact Info

Product

Resources

About